{"id":866721,"date":"2025-07-07T07:03:42","date_gmt":"2025-07-07T11:03:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-presents-data-at-esmo-gi-on-its-tissue-free-latitude-mrd-assay-demonstrating-excellent-overall-performance-in-colorectal-cancer\/"},"modified":"2025-07-07T07:03:42","modified_gmt":"2025-07-07T11:03:42","slug":"natera-presents-data-at-esmo-gi-on-its-tissue-free-latitude-mrd-assay-demonstrating-excellent-overall-performance-in-colorectal-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-presents-data-at-esmo-gi-on-its-tissue-free-latitude-mrd-assay-demonstrating-excellent-overall-performance-in-colorectal-cancer\/","title":{"rendered":"Natera Presents Data at ESMO GI on its Tissue-Free Latitude\u2122 MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Natera Presents Data at ESMO GI on its Tissue-Free Latitude\u2122 MRD<sup>*<\/sup> Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer<\/b><\/p>\n<p>AUSTIN, Texas&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54286298&amp;newsitemid=20250707280681&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=9d24dfe415e87dd9e9e2e59768c60f76\">Natera, Inc.<\/a> (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced data from a colorectal cancer (CRC) study of its tissue-free Latitude\u2122 MRD assay, which were presented at the 2025 European Society for Medical Oncology GI Congress (ESMO GI).<\/p>\n<p>\nThe clinical performance of the assay was analyzed in a cohort of ~200 patients (&gt;1,300 plasma samples) with resectable stage I-IV colorectal cancer. Samples were derived from the GALAXY arm of the CIRCULATE-Japan study, one of the largest and most comprehensive prospective studies of MRD testing in resectable CRC. Key results include:<\/p>\n<ul class=\"bwlistdisc\">\n<li><b>Excellent clinical sensitivity to recurrence<\/b>: The Latitude assay detected recurrence with 58% sensitivity in the post-surgical MRD window and 81% sensitivity in the surveillance setting, with median diagnostic lead time of 4.6 months.\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li><b>High clinical specificity<\/b>: In the surveillance setting, patient-level specificity was 92%, and sample-level specificity was 97%.\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li><b>Highly prognostic of recurrence risk<\/b>: MRD positivity was significantly associated with inferior outcomes during both the MRD (HR: 10, p&lt;0.001) and surveillance (HR: 18, p&lt;0.001) windows.\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li><b>Highly predictive of adjuvant chemotherapy (ACT) benefit<\/b>:<b \/>Among high-risk stage II and stage III patients, those who were MRD-positive after surgery derived significant benefit from ACT (p&lt;0.001), while no significant treatment benefit was observed in MRD-negative patients (p=0.54).\n<\/li>\n<\/ul>\n<p>\n\u201cThis study demonstrates strong clinical potential for Natera\u2019s tissue-free MRD assay,\u201d said Yoshiaki Nakamura, M.D., Ph.D., principal investigator of the study. \u201cWe clearly observed the prognostic and predictive value of the assay, seeing strong correlation of recurrence risk and adjuvant treatment outcomes.\u201d<\/p>\n<p>\n\u201cThese results reinforce the data previously presented at ASCO GI, where our tissue-free Latitude MRD assay demonstrated high overall concordance to Signatera\u2122 as well as strong standalone clinical performance,\u201d said Alexey Aleshin, M.D., corporate chief medical officer and general manager of oncology at Natera. \u201cWhen offered alongside Signatera, our tissue-free assay gives patients and providers the latitude to get a reliable MRD assessment even when tissue is unavailable.\u201d<\/p>\n<p><b>Notes<br \/>\n<br \/><\/b><sup>*<\/sup>MRD = Molecular residual disease<\/p>\n<p><b>About Natera<\/b><\/p>\n<p>\nNatera\u2122 is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women\u2019s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera\u2019s tests are supported by more than 300 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54286298&amp;newsitemid=20250707280681&amp;lan=en-US&amp;anchor=www.natera.com&amp;index=2&amp;md5=29afe8a8292baff8dcd7f4eee682a05c\">www.natera.com<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nAll statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera\u2019s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera\u2019s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in \u201cRisk Factors\u201d in Natera\u2019s recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.natera.com%2Fnews%2Fdefault.aspx&amp;esheet=54286298&amp;newsitemid=20250707280681&amp;lan=en-US&amp;anchor=www.natera.com%2Finvestors&amp;index=3&amp;md5=9d3261b39fd88dff601448473d8bd5dd\">www.natera.com\/investors<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=54286298&amp;newsitemid=20250707280681&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=4&amp;md5=ac5221a3d54481954f450a10743725fe\">www.sec.gov<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250707280681r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250707280681\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250707280681\/en\/<\/a><\/span><\/p>\n<p>\nInvestor Relations: Mike Brophy, CFO, Natera, Inc., <a rel=\"nofollow\" href=\"mailto:investor@natera.com\">investor@natera.com<br \/>\n<\/a><br \/>Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., <a rel=\"nofollow\" href=\"mailto:pr@natera.com\">pr@natera.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Europe United States North America Texas<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology Health Genetics Research Science Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250707280681\/en\/1736351\/3\/Natera_floret_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Natera Presents Data at ESMO GI on its Tissue-Free Latitude\u2122 MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211;Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced data from a colorectal cancer (CRC) study of its tissue-free Latitude\u2122 MRD assay, which were presented at the 2025 European Society for Medical Oncology GI Congress (ESMO GI). The clinical performance of the assay was analyzed in a cohort of ~200 patients (&gt;1,300 plasma samples) with resectable stage I-IV colorectal cancer. Samples were derived from the GALAXY arm of the CIRCULATE-Japan study, one of the largest and most comprehensive prospective studies of MRD testing in resectable CRC. Key results include: Excellent clinical sensitivity to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/natera-presents-data-at-esmo-gi-on-its-tissue-free-latitude-mrd-assay-demonstrating-excellent-overall-performance-in-colorectal-cancer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Natera Presents Data at ESMO GI on its Tissue-Free Latitude\u2122 MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-866721","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Natera Presents Data at ESMO GI on its Tissue-Free Latitude\u2122 MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/natera-presents-data-at-esmo-gi-on-its-tissue-free-latitude-mrd-assay-demonstrating-excellent-overall-performance-in-colorectal-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Natera Presents Data at ESMO GI on its Tissue-Free Latitude\u2122 MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Natera Presents Data at ESMO GI on its Tissue-Free Latitude\u2122 MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211;Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced data from a colorectal cancer (CRC) study of its tissue-free Latitude\u2122 MRD assay, which were presented at the 2025 European Society for Medical Oncology GI Congress (ESMO GI). The clinical performance of the assay was analyzed in a cohort of ~200 patients (&gt;1,300 plasma samples) with resectable stage I-IV colorectal cancer. Samples were derived from the GALAXY arm of the CIRCULATE-Japan study, one of the largest and most comprehensive prospective studies of MRD testing in resectable CRC. Key results include: Excellent clinical sensitivity to &hellip; Continue reading &quot;Natera Presents Data at ESMO GI on its Tissue-Free Latitude\u2122 MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/natera-presents-data-at-esmo-gi-on-its-tissue-free-latitude-mrd-assay-demonstrating-excellent-overall-performance-in-colorectal-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-07T11:03:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250707280681r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-presents-data-at-esmo-gi-on-its-tissue-free-latitude-mrd-assay-demonstrating-excellent-overall-performance-in-colorectal-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-presents-data-at-esmo-gi-on-its-tissue-free-latitude-mrd-assay-demonstrating-excellent-overall-performance-in-colorectal-cancer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Natera Presents Data at ESMO GI on its Tissue-Free Latitude\u2122 MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer\",\"datePublished\":\"2025-07-07T11:03:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-presents-data-at-esmo-gi-on-its-tissue-free-latitude-mrd-assay-demonstrating-excellent-overall-performance-in-colorectal-cancer\\\/\"},\"wordCount\":688,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-presents-data-at-esmo-gi-on-its-tissue-free-latitude-mrd-assay-demonstrating-excellent-overall-performance-in-colorectal-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250707280681r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-presents-data-at-esmo-gi-on-its-tissue-free-latitude-mrd-assay-demonstrating-excellent-overall-performance-in-colorectal-cancer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-presents-data-at-esmo-gi-on-its-tissue-free-latitude-mrd-assay-demonstrating-excellent-overall-performance-in-colorectal-cancer\\\/\",\"name\":\"Natera Presents Data at ESMO GI on its Tissue-Free Latitude\u2122 MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-presents-data-at-esmo-gi-on-its-tissue-free-latitude-mrd-assay-demonstrating-excellent-overall-performance-in-colorectal-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-presents-data-at-esmo-gi-on-its-tissue-free-latitude-mrd-assay-demonstrating-excellent-overall-performance-in-colorectal-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250707280681r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-07-07T11:03:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-presents-data-at-esmo-gi-on-its-tissue-free-latitude-mrd-assay-demonstrating-excellent-overall-performance-in-colorectal-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-presents-data-at-esmo-gi-on-its-tissue-free-latitude-mrd-assay-demonstrating-excellent-overall-performance-in-colorectal-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-presents-data-at-esmo-gi-on-its-tissue-free-latitude-mrd-assay-demonstrating-excellent-overall-performance-in-colorectal-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250707280681r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250707280681r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/natera-presents-data-at-esmo-gi-on-its-tissue-free-latitude-mrd-assay-demonstrating-excellent-overall-performance-in-colorectal-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Natera Presents Data at ESMO GI on its Tissue-Free Latitude\u2122 MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Natera Presents Data at ESMO GI on its Tissue-Free Latitude\u2122 MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-presents-data-at-esmo-gi-on-its-tissue-free-latitude-mrd-assay-demonstrating-excellent-overall-performance-in-colorectal-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Natera Presents Data at ESMO GI on its Tissue-Free Latitude\u2122 MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer - Market Newsdesk","og_description":"Natera Presents Data at ESMO GI on its Tissue-Free Latitude\u2122 MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211;Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced data from a colorectal cancer (CRC) study of its tissue-free Latitude\u2122 MRD assay, which were presented at the 2025 European Society for Medical Oncology GI Congress (ESMO GI). The clinical performance of the assay was analyzed in a cohort of ~200 patients (&gt;1,300 plasma samples) with resectable stage I-IV colorectal cancer. Samples were derived from the GALAXY arm of the CIRCULATE-Japan study, one of the largest and most comprehensive prospective studies of MRD testing in resectable CRC. Key results include: Excellent clinical sensitivity to &hellip; Continue reading \"Natera Presents Data at ESMO GI on its Tissue-Free Latitude\u2122 MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-presents-data-at-esmo-gi-on-its-tissue-free-latitude-mrd-assay-demonstrating-excellent-overall-performance-in-colorectal-cancer\/","og_site_name":"Market Newsdesk","article_published_time":"2025-07-07T11:03:42+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250707280681r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-presents-data-at-esmo-gi-on-its-tissue-free-latitude-mrd-assay-demonstrating-excellent-overall-performance-in-colorectal-cancer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-presents-data-at-esmo-gi-on-its-tissue-free-latitude-mrd-assay-demonstrating-excellent-overall-performance-in-colorectal-cancer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Natera Presents Data at ESMO GI on its Tissue-Free Latitude\u2122 MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer","datePublished":"2025-07-07T11:03:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-presents-data-at-esmo-gi-on-its-tissue-free-latitude-mrd-assay-demonstrating-excellent-overall-performance-in-colorectal-cancer\/"},"wordCount":688,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-presents-data-at-esmo-gi-on-its-tissue-free-latitude-mrd-assay-demonstrating-excellent-overall-performance-in-colorectal-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250707280681r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-presents-data-at-esmo-gi-on-its-tissue-free-latitude-mrd-assay-demonstrating-excellent-overall-performance-in-colorectal-cancer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-presents-data-at-esmo-gi-on-its-tissue-free-latitude-mrd-assay-demonstrating-excellent-overall-performance-in-colorectal-cancer\/","name":"Natera Presents Data at ESMO GI on its Tissue-Free Latitude\u2122 MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-presents-data-at-esmo-gi-on-its-tissue-free-latitude-mrd-assay-demonstrating-excellent-overall-performance-in-colorectal-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-presents-data-at-esmo-gi-on-its-tissue-free-latitude-mrd-assay-demonstrating-excellent-overall-performance-in-colorectal-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250707280681r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-07-07T11:03:42+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-presents-data-at-esmo-gi-on-its-tissue-free-latitude-mrd-assay-demonstrating-excellent-overall-performance-in-colorectal-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/natera-presents-data-at-esmo-gi-on-its-tissue-free-latitude-mrd-assay-demonstrating-excellent-overall-performance-in-colorectal-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-presents-data-at-esmo-gi-on-its-tissue-free-latitude-mrd-assay-demonstrating-excellent-overall-performance-in-colorectal-cancer\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250707280681r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250707280681r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/natera-presents-data-at-esmo-gi-on-its-tissue-free-latitude-mrd-assay-demonstrating-excellent-overall-performance-in-colorectal-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Natera Presents Data at ESMO GI on its Tissue-Free Latitude\u2122 MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/866721","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=866721"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/866721\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=866721"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=866721"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=866721"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}